Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

31
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
31
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

39
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
39
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

95
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
95
Antibiotic Selection00:57

Antibiotic Selection

62.1K
Overview
62.1K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

835
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
835

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From bench to bedside: how dynamic hollow-fibre in vitro infection experiments and mathematical modelling can inform PK/PD targets for teicoplanin.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations.

The Lancet. Microbe·2026
Same author

Bioactive cationic lipidated oligomers (CLOs) as antimicrobial materials: metabolomic insights into MRSA membrane disruption.

Biomaterials science·2026
Same author

AI for NONMEM Coding in Pharmacometrics Research and Education: Shortcut or Pitfall?

CPT: pharmacometrics & systems pharmacology·2025
Same author

Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant <i>Klebsiella pneumoniae</i>.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Mar 29, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

28.0K

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Phillip J Bergen1, Zackery P Bulman2, Cornelia B Landersdorfer3,1

  • 1Centre for Medicine Use and Safety, Monash University, Melbourne, Australia.

Infectious Diseases and Therapy
|December 10, 2015
PubMed
Summary
This summary is machine-generated.

Polymyxin combination therapy, including colistin (CMS) and polymyxin B, shows promise for enhancing bacterial killing and combating resistance. However, robust clinical and preclinical data are still limited, necessitating further investigation.

Keywords:
ColistinColistin methanesulfonateCombinationPharmacodynamicPolymyxin BPolymyxins

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

Related Experiment Videos

Last Updated: Mar 29, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

28.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.8K

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Polymyxin combination therapy is gaining clinical traction.
  • Emerging pharmacokinetic (PK) and pharmacodynamic (PD) data indicate potential risks with monotherapy for colistin (CMS) and polymyxin B.
  • Combination therapy is proposed to improve bacterial killing and mitigate resistance development.

Purpose of the Study:

  • To provide a comprehensive overview of clinical and preclinical research on colistin (CMS)/colistin and polymyxin B combination therapies.
  • To evaluate the existing evidence supporting polymyxin combination strategies.

Main Methods:

  • Review of existing clinical and preclinical investigations.
  • Analysis of in vitro data, including dynamic models.
  • Assessment of animal and human clinical study designs and limitations.

Main Results:

  • Significant in vitro data support the efficacy of polymyxin combinations.
  • Preclinical animal data are often of poor quality and lack robust study design.
  • Clinical data are predominantly from retrospective analyses and small prospective studies.

Conclusions:

  • Polymyxin combination therapy warrants further rigorous investigation due to promising in vitro results.
  • Limitations in current preclinical and clinical data highlight the need for high-quality studies.
  • Careful consideration of existing evidence is crucial when implementing polymyxin combination strategies.